Skip to main content
Clinical Trials/NCT04558957
NCT04558957
Completed
Not Applicable

Prospective, Multi-centre Clinical Study to Assess the Safety and Efficacy of Mechanochemical Ablation With the Use of Flebogrif in Patients With Great Saphenous Vein Insufficiency

Balton Sp.zo.o.4 sites in 1 country200 target enrollmentAugust 8, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Venous Insufficiency, CVI
Sponsor
Balton Sp.zo.o.
Enrollment
200
Locations
4
Primary Endpoint
Primary efficacy endpoint: Occlusion rate
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The objective of the study is to collect clinical data of patients in whom Flebogrif® will have been used for mechanochemical ablation of incompetent veins in the follow-up period, as related to the safety, clinical effectiveness, properties and advantages of Flebogrif®.

The proposed study is a prospective, multi-centre clinical trial assessing the safety, efficacy and quality of Flebogrif® in a population of patients with the incompetent great saphenous vein, who require surgical treatment.

Registry
clinicaltrials.gov
Start Date
August 8, 2019
End Date
April 28, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Balton Sp.zo.o.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Primary efficacy endpoint: Occlusion rate

Time Frame: 3 months

Primary efficacy endpoint: Occlusion rate of the great saphenous vein in the treated segment at 3 months

Primary safety endpoint: Rate of SAE

Time Frame: 30 days after the procedure

Primary safety endpoint: Rate of serious adverse events within 30 days after the procedure

Secondary Outcomes

  • Assessment of pain within 0-7 days after the procedure: Visual Analogue Scale(0-7 days after procedure)
  • Period needed to resume normal activities(up to 2 years after the treatment)
  • Number of Participants with no reflux in treated segment of the vein(1, 3, 6, 12, 18, 24 months)
  • Period needed to return to work (sick leave period)(up to 2 years after the treatment)
  • Clinical success - changes in rVCSS(12 and 24 months)
  • Complications rate(up to 2 years after the treatment)
  • Occlusion rate(1, 6, 12, 18, 24 months)
  • Change in quality of life by Aberdeen Varicose Vein Questionnaire(12 and 24 months)
  • Assessment of pain during the procedure(During procedure)
  • Assessment of the need for analgesic treatment(0-7 days after procedure)

Study Sites (4)

Loading locations...

Similar Trials